NEW YORK (AP) -- A published report of a private buyout offer for Omrix Biopharmaceuticals Inc. lifted the biotechnology company’s stock Monday. Shares rose 26 cents, or 1.2 percent, to $22.39. The stock has traded between $11.81 and $39.07 over the last 52 weeks. On Monday, the Israel-based business publication Globes reported that a U.S. hedge fund offered $25 per share for the New York-based biotech company. It also said Omrix recently rebuffed a buyout offer from distribution partner Johnson & Johnson. The report cited unnamed sources.
